Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04856787

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC) Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Study of SHR-1701 or Placebo in Combination With BP102 (Biosimilar to Bevacizumab) and XELOX in First-line Treatment of mCRC

Clinical Trial Summary

This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04856787
Study type Interventional
Source Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact Qing Yang, M.D
Phone +86 021-61053363
Email yangqing@hrglobe.cn
Status Recruiting
Phase Phase 2/Phase 3
Start date June 22, 2021
Completion date November 6, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02069704 - Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Phase 1
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. Phase 1
Completed NCT00594984 - Phase I/II Combination With Irinotecan- Erbitux Phase 1/Phase 2
Recruiting NCT03829462 - Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients Phase 3
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Completed NCT05420909 - A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
Not yet recruiting NCT06089330 - A Study of JMT101 in Patients With Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Active, not recruiting NCT03511963 - A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC Phase 3
Active, not recruiting NCT05839951 - An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions